Device Energy

Megadyne

Payments companies reported to CMS as associated with Megadyne. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$93Kassociated payments (2023-2025)

681clinicians with associated payments

7companies reporting

By year

2023 $52K

2024 $28K

2025 $13K

Payments reported as associated with Megadyne, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Surgery $44K

Medical $17K

Surgical Oncology $4,603

Obstetrics & Gynecology $4,533

Physician Assistant $4,399

Plastic Surgery $2,074

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Megadyne

These are the largest totals companies reported as associated with Megadyne. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

Clinician	Location	Specialty	Associated payments (2023-2025)
Jason Radecke	Sebastian, FL	Surgery	$33,484.01
Emily Baron	St Johns, FL	Medical	$16,513.79
Peter Dipasco	Saint Louis, MO	Surgical Oncology	$3,983.90
Anne Gregg	Melbourne, FL	Physician Assistant	$1,852.18
Jennifer Schwartz	Needham, MA	Obesity Medicine (Internal Medicine)	$563.75
Carrie Rossi	Trumbull, CT	Physician Assistant	$507.18
Kirsten Greene	Charlottesville, VA	Urology	$505.00
Cindy Anderson	Fairfield, CT	Surgical	$466.37
Michael Hann	Trumbull, CT	Surgical	$411.48
Eugene Rubach	Manhasset, NY	Surgery	$398.40

Prescribed Megadyne?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

What this means, and what it doesn't

These payments are legal and common. Drug and device makers routinely pay for meals at educational events, consulting, speaking, travel, and research. Companies are required by federal law to report them; that's why this data exists.
A payment is not evidence of wrongdoing. Most clinicians who accept industry payments provide excellent care. Research payments in particular often reflect participation in clinical trials.
Context beats raw numbers. A few hundred dollars in sandwiches over several years is typical. What's worth understanding is scale, source, and purpose, which is what this page shows.
The data comes from companies, not doctors. Figures are "as reported to CMS" by the paying companies. Clinicians can dispute records through CMS's official process.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.